Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: A docking study

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 2, 2012, Pages 142-147

  Shakil, Shazi ^a   Kamal, Mohammad A ^a   Tabrez, Shams ^a   Abuzenadah, Adel M ^a   Chaudhary, Adeel G A ^a   Damanhouri, Ghazi A ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Docking; Enzyme inhibition; Human brain acetylcholinesterase; Methotrexate

Indexed keywords

ACETYLCHOLINESTERASE; CYCLOPHOSPHAMIDE; METHOTREXATE;

ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME STRUCTURE; EXPERIMENTAL STUDY; HUMAN; MOLECULAR DOCKING; MOLECULAR INTERACTION; X RAY CRYSTALLOGRAPHY;

EID: 84860471051     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800269669     Document Type: Article

References (34)

1. Kamal, M.A.; Nasim, F.H.; Al-Jafari, A.A. Investigation of the effect of anti-neoplastic drugs, cyclophosphamide, cisplatin and methotrexate on the turnover kinetics of human erythrocyte acetylcholinesterase. Biochem. Mol. Biol. Int., 1996a, 39(2), 293-302.
2. Baranauskaite, A.; Raffayová, H.; Kungurov, N.; Kubanova, A.; Venalis, A.; Helmle, L.; Srinivasan, S.; Nasonov, E.; Vastesaeger, N.; RESPOND investigators. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis inmethotrexate-naive patients: the RESPOND study. Ann. Rheum. Dis., 2011, 71(4), 541-548.
3. Kremer, J.M.; Cohen, S.; Wilkinson, B.E.; Connell, C.A.; French, J.L.; Gomez-Reino, J.; Gruben, D.; Kanik, K.S.; Krishnaswami, S.; Pascual-Ramos, V.; Wallenstein, G.; Zwillich, S.H. A Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP- 690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid0020arthritis andinadequateresponseto methotrexate alone. Arthritis Rheum., 2011, [Epub ahead of print].
4. Shuper, A.; Stark, B.; Kornreich, L.; Cohen, I.J.; Avrahami, G.; Yaniv, I. Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. Isr. Med. Assoc. J., 2002, 4(11), 1050-1053.
5. Aradillas, E.; Arora, R.; Gasperino, J. Methotrexate-induced posterior reversible encephalopathy syndrome. J. Clin. Pharm. Ther., 2011, 36(4), 529-536.
6. Yang, M.; Kim, J.S.; Kim, J.; Kim, S.H.; Kim, J.C.; Kim, J.; Wang, H.; Shin,T.; Moon, C. Neurotoxicity of methotrexate to hippocampal cells in vivo and in vitro. Biochem. Pharmacol., 2011, 82(1), 72-80.
7. Silman, I.; Sussman, J.L. Acetylcholinesterase: how is structure related to function? Chem. Biol. Interact., 2008, 175(1-3), 3-10.
8. Darvesh, S.; Hopkins, D.A.; Geula, C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci., 2003a, 4(2), 131-138.
9. Silman, I.; Sussman, J.L. Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology. Curr. Opin. Pharmacol., 2005, 5(3), 293-302.
10. Munoz-Delgado, E.; Montenegro, M.F.; Campoy, F.J.; Moral-Naranjo, M.T.; Cabezas-Herrera, J.; Kovacs, G.; Vidal, C.J. Expression of cholinesterases in human kidney and its variation in renal cell carcinoma types. FEBS J., 2010, 277(21), 4519-4529.
11. Howland, R.H. Alternative drug therapies for dementia. J. Psychosoc. Nurs. Ment. Health Serv., 2011, 49(5), 17-20.
12. Stephenson, J.; Czepulkowski, B.; Hirst, W.; Mufti, G.J. Deletion of the acetylcholinesterase locus at 7q22 associated with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Leuk. Res., 1996, 20, 235-241.
13. Darreh-Shori, T.; Soininen, H. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies. Curr. Alzheimer Res., 2010, 7(1), 67-73.
14. Mehndiratta, M. M.; Pandey, S.; Kuntzer, T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst. Rev., 2011, 2, CD006986.
15. Nunes, B. The use of cholinesterases in ecotoxicology. Rev. Environ. Contam. Toxicol., 2011, 212, 29-59.
16. Kamal, M.A.; Nasim, F.H.; Al-Jafri, A.A. In vitro inhibition of human erythrocyte acetylcholinesterase(EC3.1.1.7) by an antineoplastic drug methotrexate. Mol. Cell Biochem., 1996b, 159(1), 47-53.
17. Al-Jafari, A.; Al-Khwyter, F.; Kamal, M.A.; Alhomida, A.S. Kinetics for camel (Camelus dromedarius) retina acetylcholinesterase inhibition by methotrexate in vitro. Jpn. J. Pharmacol., 1996, 72(1), 49-55.
18. Dukic, S.F.; Kaltenbach, M.L.; Heurtaux, T; Hoizey, G.; Lallemand, A.; Vistelle, R. Influence of C6 and CNS1 brain tumors on methotrexate pharmacokinetics in plasma and brain tissue. J. Neurooncol., 2004, 67(1-2), 131-138.
19. Leblanc, G.A.; Waxman, D.J. Interaction of anticancer drugs with hepatic monooxygenase. Drug Meta Rev., 1989, 20(2-4), 395-439.
20. Sadzuka, Y., Shoji, T.; Takino, Y. Effect of cisplatin on the activities of enzymes which protect against lipid peroxidation. Biochem. Pharmacol., 1992, 43, 1872-1875.
21. Shakil, S.; Khan, A.U. Interaction of CTX-M-15 enzyme with cefotaxime: a molecular modelling and docking study. Bioinformation, 2010, 4(10), 468-472.
22. Shakil, S.; Khan, A.U. Interaction of 2009 CTX-M variants with drugs and inhibitors: a molecular modelling and docking study. J. Proteomics Bioinformatics., 2010, 3, 130-134.
23. An, Y.J.; Lee, J.H.; Jung, H.I.; Sohn, S.G.; Lee, J.J.; Park, K.S.; Wu, X.; Jeong, B.C.; Kang, C.M.; Cha, S.S.; Lee, S.H. Crystallization and preliminary X-ray crystallographic analysis of CTX-M-15, an extended-spectrum -lactamase conferring worldwide emerging antibiotic resistance. Protein Pept. Lett., 2011, 18(9), 858-862.
24. Shakil, S.; Khan, R., Tabrez, S.; Alam, Q.; Jabir, N.R.; Sulaiman, M.I.; Greig, N.H.; Kamal, M.A. Interaction of Human Brain Acetylcholinesterase With Cyclophosphamide: A Molecular Modeling And Docking Study. CNS Neurol. Disord. Drug Targets, 2011, 11(01), in press.
25. Darvesh, S.; Walsh, R.; Kumar, R.; Caines, A.; Roberts, S.; Magee, D.; Rockwood, K.; Martin, E. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis. Assoc. Disord., 2003b, 17(2), 117-126.
26. Al-Jafari, A.A.; Kamal, M.A.; Greig, N.H.; Alhomida, A.S.; Perry, E.R. Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine phenserine. Biochem. Biophys. Res. Commun., 1998, 248(1), 180-185.
27. Pepeu, G.; Giovannini, M.G. Cholinesterase inhibitors and beyond. Curr. Alzheimer Res., 2009, 6(2), 86-96.
28. Xu, Y.; Colletier, J.P.; Weik, M.; Jiang, H.; Moult, J.; Silman, I.; Sussman, J.L. Flexibility of aromatic residues in the active-site gorge of acetylcholinesterase: X-ray versus molecular dynamics. Biophys. J., 2008, 95(5), 2500-2511.
29. Pang, Y.P.; Kozikowski, A.P. Prediction of the binding site of 1-benzyl-4-[(5,6-di- methoxy-l-indanon-2-yl)methyl]piperidine in acetyl- cholinesterase by docking studies with the SYSDOC program. J. Comput. Aided Mol. Des., 1994, 8, 683-693.
30. Al-Jafri, A.A.; Shakil, S.; Reale, M.; Kamal, M.A. Human platelet acetylcholinesterase inhibition by cyclophosphamide: a combined experimental and computational approach. CNS Neurol. Disord. Drug Targets, 2011, 10(8), 928-935.
31. Greenblatt, H.M.; Dvir, H.; Silman, I.; Sussman, J.L. Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease. J. Mol. Neurosci., 2003, 20(3), 369-383.
32. Sathasivam,S.Current and emerging treatments for the management of myasthenia gravis. Ther. Clin. Risk Manag., 2011, 7, 313-323.
33. Lau, A.Y.; Chan, A.Y.; Mok, V.C. Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment. Hong Kong Med. J., 2011, 17(1), 77-79.
34. Heckmann, J.M.; Rawoot, A.; Bateman, K; Renison, R.; Badri, M. A single-blinded trial of methotrexate versus azathioprine as steroid- sparingagents in generalized myasthenia gravis. BMC Neurol., 2011, 11, 97.